NCT06534424View on ClinicalTrials.gov

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

NACompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Interventions
OTHER

Best Practice

Receive standard care

PROCEDURE

Biospecimen Collection

Undergo collection of blood or mouthwash sample

OTHER

Counseling

Receive tailored counseling

PROCEDURE

Discussion

Participate in phone discussion

PROCEDURE

Genotyping

Undergo genotyping

PROCEDURE

Molecular Risk Assessment

Undergo enhanced risk assessment

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

43210

Ohio State University Comprehensive Cancer Center, Columbus

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT06534424 - Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study | Biotech Hunter | Biotech Hunter